Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
15 06 2022
Historique:
received: 06 05 2021
accepted: 13 05 2022
entrez: 15 6 2022
pubmed: 16 6 2022
medline: 18 6 2022
Statut: epublish

Résumé

Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with significant heterogeneity in disease progression. Existing clinical models of progression risk do not fully capture this heterogeneity. Here we integrate 42 genetic alterations from 214 SMM patients using unsupervised binary matrix factorization (BMF) clustering and identify six distinct genetic subtypes. These subtypes are differentially associated with established MM-related RNA signatures, oncogenic and immune transcriptional profiles, and evolving clinical biomarkers. Three genetic subtypes are associated with increased risk of progression to active MM in both the primary and validation cohorts, indicating they can be used to better predict high and low-risk patients within the currently used clinical risk stratification models.

Identifiants

pubmed: 35705541
doi: 10.1038/s41467-022-30694-w
pii: 10.1038/s41467-022-30694-w
pmc: PMC9200804
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3449

Subventions

Organisme : Cancer Research UK
ID : A28770
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA205954
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121176
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Blood. 2017 Nov 30;130(22):2392-2400
pubmed: 28847998
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Stat Med. 2011 May 10;30(10):1105-17
pubmed: 21484848
Blood Cancer J. 2016 Jul 29;6(7):e454
pubmed: 27471870
Nat Genet. 2016 Jun;48(6):600-606
pubmed: 27111033
Bioinformatics. 2011 Sep 15;27(18):2601-2
pubmed: 21803805
Nat Commun. 2014;5:2997
pubmed: 24429703
Blood. 2005 Jul 1;106(1):296-303
pubmed: 15755896
Cancer Cell. 2009 Oct 6;16(4):309-23
pubmed: 19800576
Blood Cancer Discov. 2020 Nov;1(3):258-273
pubmed: 33392515
Cell. 2013 Feb 14;152(4):714-26
pubmed: 23415222
J Clin Oncol. 2020 Jul 20;38(21):2380-2389
pubmed: 32442065
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
N Engl J Med. 2007 Jun 21;356(25):2582-90
pubmed: 17582068
Cell. 2014 Aug 14;158(4):929-944
pubmed: 25109877
Genome Biol. 2019 Nov 1;20(1):228
pubmed: 31675989
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nat Commun. 2021 Jan 12;12(1):293
pubmed: 33436579
Blood. 2010 Oct 7;116(14):2543-53
pubmed: 20574050
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Leukemia. 2020 Jan;34(1):322-326
pubmed: 31439946
Nat Commun. 2019 Aug 23;10(1):3835
pubmed: 31444325
Nat Methods. 2014 Mar;11(3):333-7
pubmed: 24464287
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16420-16429
pubmed: 31371506
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Nat Commun. 2015 Apr 23;6:6997
pubmed: 25904160
Science. 2020 Sep 11;369(6509):1318-1330
pubmed: 32913098
Nat Commun. 2018 Oct 26;9(1):4453
pubmed: 30367051
Nucleic Acids Res. 2012 Oct;40(19):9379-91
pubmed: 22879375
Blood. 2006 Sep 15;108(6):2020-8
pubmed: 16728703
Nucleic Acids Res. 2013 Apr 1;41(6):e67
pubmed: 23303777
Nucleic Acids Res. 2018 Nov 16;46(20):10546-10562
pubmed: 30295871
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
N Engl J Med. 2002 Feb 21;346(8):564-9
pubmed: 11856795
Nature. 2011 Mar 24;471(7339):467-72
pubmed: 21430775
Nat Methods. 2018 Jul;15(7):531-534
pubmed: 29941871
Blood Cancer J. 2020 Oct 16;10(10):102
pubmed: 33067414
Lancet Oncol. 2020 Dec;21(12):1630-1642
pubmed: 33129376
J Clin Oncol. 2015 Nov 20;33(33):3911-20
pubmed: 26282654
Hum Mutat. 2015 Apr;36(4):E2423-9
pubmed: 25703262
PLoS One. 2012;7(4):e35236
pubmed: 22539962
Genome Res. 2017 Dec;27(12):2025-2039
pubmed: 29066617
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179

Auteurs

Mark Bustoros (M)

Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.
Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Shankara Anand (S)

Broad Institute of MIT & Harvard, Cambridge, MA, USA.
Boston University School of Medicine, Boston, MA, USA.

Romanos Sklavenitis-Pistofidis (R)

Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.
Broad Institute of MIT & Harvard, Cambridge, MA, USA.

Robert Redd (R)

Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.

Eileen M Boyle (EM)

Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

Benny Zhitomirsky (B)

Broad Institute of MIT & Harvard, Cambridge, MA, USA.

Andrew J Dunford (AJ)

Broad Institute of MIT & Harvard, Cambridge, MA, USA.

Yu-Tzu Tai (YT)

Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.

Selina J Chavda (SJ)

Division of Hematology, University College London, London, UK.

Cody Boehner (C)

Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.

Carl Jannes Neuse (CJ)

Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.
University of Münster Medical School, Münster, Germany.

Mahshid Rahmat (M)

Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.

Ankit Dutta (A)

Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.

Tineke Casneuf (T)

Janssen Research and Development, Beerse, Belgium.

Raluca Verona (R)

Janssen Research and Development, Spring House, PA, USA.

Efstathis Kastritis (E)

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.

Lorenzo Trippa (L)

Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.

Chip Stewart (C)

Broad Institute of MIT & Harvard, Cambridge, MA, USA.

Brian A Walker (BA)

Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, USA.

Faith E Davies (FE)

Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

Meletios-Athanasios Dimopoulos (MA)

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.

P Leif Bergsagel (PL)

Division of Hematology, Mayo Clinic, Scottsdale, AZ, USA.

Kwee Yong (K)

Division of Hematology, University College London, London, UK.

Gareth J Morgan (GJ)

Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

François Aguet (F)

Broad Institute of MIT & Harvard, Cambridge, MA, USA.

Gad Getz (G)

Broad Institute of MIT & Harvard, Cambridge, MA, USA. gadgetz@broadinstitute.org.
Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA, USA. gadgetz@broadinstitute.org.

Irene M Ghobrial (IM)

Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu.
Broad Institute of MIT & Harvard, Cambridge, MA, USA. Irene_Ghobrial@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH